Skip to content
Menu

Citizens Maintains Market Outperform on Haemonetics, Raises Price Target to $144

Benzinga Newsdesk 5 days ago

Analyst RatingsNewsPrice Target

This page contains a summary, not the full article. Continue to benzinga.com to read the original report.

Citizens analyst Daniel Stauder maintains Haemonetics (NYSE:HAE) with a Market Outperform and raises the price target from $115 to $144.

Citizens analyst Daniel Stauder maintains Haemonetics (NYSE:HAE) with a Market Outperform and raises the price target from $115 to $144.

Read at benzinga.com

← All stock news